share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%), etc.

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%), etc.

Avalo Therapeutics | SC 13G：超過5%持股股東披露文件-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%)等
美股sec公告 ·  05/13 12:44
Moomoo AI 已提取核心訊息
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
2024年5月1日，Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC以及個人克里斯托弗·斯塔爾和大衛·莫德斯特（統稱爲 “申報人”）向美國證券交易委員會提交了附表13G，表示集體擁有Avalo Therapeutics, Inc.78,255股股票。這約佔該公司已發行普通股的7.6％。根據第13d-1（c）條提交的文件表明，這些股份是實益所有的，申報人對這些股票擁有共同的投票權和處置權。所有申報人的主要營業地址均在康涅狄格州斯坦福德。發行人Avalo Therapeutics, Inc. 總部位於馬里蘭州羅克維爾。該文件稱，收購這些股票不是爲了改變或影響發行人的控制權。
2024年5月1日，Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC以及個人克里斯托弗·斯塔爾和大衛·莫德斯特（統稱爲 “申報人”）向美國證券交易委員會提交了附表13G，表示集體擁有Avalo Therapeutics, Inc.78,255股股票。這約佔該公司已發行普通股的7.6％。根據第13d-1（c）條提交的文件表明，這些股份是實益所有的，申報人對這些股票擁有共同的投票權和處置權。所有申報人的主要營業地址均在康涅狄格州斯坦福德。發行人Avalo Therapeutics, Inc. 總部位於馬里蘭州羅克維爾。該文件稱，收購這些股票不是爲了改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息